Category - Developments

Developments

Myovant Sciences updates positive data from Phase 3 prostate cancer trial

Myovant Sciences’ (NASDAQ:MYOV) reported additional positive results from its Phase 3 HERO study of once-daily, oral relugolix in men with advanced prostate cancer. In the primary endpoint responder analysis, 97% of men...

May 29, 2020

Developments

AVEO Oncology reports positive overall survival results from Phase 3 RCC study

AVEO Oncology (NASDAQ:AVEO) reported positive final overall survival results from its Phase 3 TIVO-3 trial comparing tivozanib to sorafenib in third- and fourth-line renal cell carcinoma (RCC). The trial met the...

May 29, 2020

Developments

Repare Therapeutics in research collaboration with Bristol Myers

Closely-held Repare Therapeutics inked an exclusive, worldwide research collaboration with Bristol Myers Squibb (NYSE:BMY). Under the accord, the companies will leverage Repare’s CRISPR-enabled genome-wide synthetic...

May 28, 2020

Developments

Cardiff Oncology onvansertib gets FDA fast track designation for colorectal cancer

Cardiff Oncology’s (NASDAQ:CRDF) onvansertib received FDA fast track designation for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The company is currently assessing...

May 28, 2020

Developments

Zynerba Pharmaceuticals reports positive topline results from Phase 2 trial of Zygel in ASD

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported positive topline data from its Phase 2 trial of Zygel for the treatment of autism spectrum disorder (ASD). Zygel is a cannabidiol-based gel that provides controlled...

May 27, 2020

Developments

IntelGenx schedules meeting with the FDA to discuss RIZAPORT NDA

The FDA has granted IntelGenx Technologies’ (TSXV:IGX; OTCQX:IGXT) request for a Type A meeting to discuss the company’s RIZAPORT VersaFilm program. The meeting is scheduled for June 10, 2020. On March...

May 27, 2020

Developments

Protara gets FDA fast track designation for intestinal failure-associated liver disease

Protara Therapeutics’ (NASDAQ:TARA) IV choline chloride received FDA fast track designation for the treatment of intestinal failure-associated liver disease (IFALD). IFALD occurs in patients who have been receiving...

May 26, 2020

Developments

TransMedics reports positive topline results from liver transplant trial

TransMedics Group’s (NASDAQ:TMDX) pivotal Organ Care System (OCS) liver trial, called PROTECT, achieved its primary and secondary effectiveness and safety endpoints. TransMedics’ OCS technology addresses the major...

May 26, 2020

Developments

Study with Daxor BVA-100 published in Circulation

Blood volume outcome data has been published in the American Heart Association journal, Circulation, utilizing Daxor’s (NYSE American:DXR) BVA-100 blood volume measurement device to determine the primary endpoint...

May 22, 2020

Developments

Cidara doses first patient in Phase 3 rezafungin trial

Cidara Therapeutics (NASDAQ:CDTX) dosed the first patient in its Phase 3 trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation. The...

May 21, 2020

Category - Developments

Myovant Sciences updates positive data from Phase 3 prostate cancer trial

AVEO Oncology reports positive overall survival results from Phase 3 RCC study

Repare Therapeutics in research collaboration with Bristol Myers

Cardiff Oncology onvansertib gets FDA fast track designation for colorectal cancer

Zynerba Pharmaceuticals reports positive topline results from Phase 2 trial of Zygel in ASD

IntelGenx schedules meeting with the FDA to discuss RIZAPORT NDA

Protara gets FDA fast track designation for intestinal failure-associated liver disease

TransMedics reports positive topline results from liver transplant trial

Study with Daxor BVA-100 published in Circulation

Cidara doses first patient in Phase 3 rezafungin trial

General

More